Neonatal hypoxia and pulmonary vasospasm: response to tolazoline

J Pediatr. 1976 Oct;89(4):617-21. doi: 10.1016/s0022-3476(76)80403-9.

Abstract

Forty-six neonates with hypoxemia were treated with tolazoline, a pulmonary vasodilator, within the first two days of life. Eight of ten (80%) infants without apparent lung disease responded with a mean increase in PaO2 of 116 torr within one hour of beginning tolazoline infusions. One of the responding infants and two nonresponders died. Thirty-six additional infants with a variety of pulmonary disorders had severe hypoxemia which was refractory to mechanical ventilation. Twenty-one (58%) responded with a mean increase in PaO2 of 130 torr within one hour after beginning tolazoline and 13 (62%) of these survived. Fifteen patients had little or no improvement in PaO2 following tolazoline and only three (20%) of these infants survived. Responders could not be distinguished from nonresponders by clinical or laboratory features prior to therapy with tolazoline. Fourteen infants experienced complications possibly related to tolazoline.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Female
  • Gastrointestinal Hemorrhage / chemically induced
  • Humans
  • Hypoxia / drug therapy*
  • Infant, Newborn
  • Infant, Newborn, Diseases / drug therapy*
  • Lung Diseases / drug therapy*
  • Male
  • Pulmonary Circulation*
  • Tolazoline / adverse effects
  • Tolazoline / therapeutic use*

Substances

  • Tolazoline